|
Exact Sciences Corp. is a molecular diagnostics company with an initial focus on the early detection and prevention of colorectal cancer.〔(【引用サイトリンク】url=http://www.marketwatch.com/investing/stock/EXAS/profile )〕 The company was founded in 1995 in Marlborough, Massachusetts and today is headquartered in Madison, Wisconsin. In August 2014, the U.S. Food and Drug Administration (FDA) approved the company’s at-home stool DNA screening test, Cologuard, for the noninvasive detection of colorectal cancers and pre-cancers. A 10,000-patient pivotal trial found that the test identified 92 percent of colon cancers and 69 percent of high-risk precancers (high-grade dysplasia) that are most likely to develop into cancer with 87 percent specificity. The results of this study were published in the April 2014 issue of the New England Journal of Medicine. Stool DNA testing is included in the colorectal cancer screening guidelines of the American Cancer Society. Exact Sciences is now developing a pipeline of diagnostic tests for the early detection of lung, pancreatic and esophageal cancers. The company was named to the InBusiness Madison “Best Companies to Work For” list in 2014 and received a 2015 American Business Awards Gold Stevie for Company of the Year in the Health Products & Services category.〔(【引用サイトリンク】url=http://www.stevieawards.com/pubs/awards/403_2949_25773.cfm )〕 ==References== 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Exact Sciences (company)」の詳細全文を読む スポンサード リンク
|